Effect of irbesartan on angiotensin II -induced hypertrophy of human proximal tubular cells

Chinese Medical Journal

Volumn 117, Issue 4, 2004, Pages 547-551

  Liu, Bi Cheng ^a   Sun, Jing ^a   Chen, Qi ^b   Luo, Dong Dong ^a   Ma, Kun Ling ^a   Ruan, Xiong Zhong ^c  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Angiotensin II; Epithelial cells; Hypertrophy; Irbesartan

Indexed keywords

ANGIOTENSIN; IRBESARTAN;

ARTICLE; CELL CYCLE; CELL LINE; CELL SIZE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; KIDNEY HYPERTROPHY; KIDNEY PROXIMAL TUBULE; PROTEIN CONTENT; PROTEIN SYNTHESIS; SCANNING ELECTRON MICROSCOPY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BIPHENYL COMPOUNDS; CELL CYCLE; CELLS, CULTURED; HUMANS; HYPERTROPHY; KIDNEY TUBULES, PROXIMAL; PROTEIN BIOSYNTHESIS; TETRAZOLES;

EID: 2342625269     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Gerth J, Kriegsmann J, Trinh TT, et al. Induction of p27KIP1 after unilateral ureteral obstruction is independent of angiotensin II. Kidney Int 2002;61:68-79.
2. Awazu M, Omori S, Ishikura K, et al. The lack of cyclin kinase inhibitor p27 (Kip1) ameliorates progression of diabetic nephropathy. J Am Soc Nephrol 2003;14:699-708.
3. Liu B, Preisig PA. Compensatory renal hypertrophy is mediated by a cell cycle-dependent mechanism. Kidney Int 2002;62:1650-1658.
4. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 2002;110:1753-1758.
5. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertensin 2001;38:635-638.
6. Zhang SL, To C, Chen X, et al. Effect of renin-angiotensin system blockade on the expression of the angiotensinogen gene and induction of hypertrophy in rat kidney proximal tubular cells. Exp Nephrol 2001;9:109-117.
7. Gross ML, El-Shakmak A, Szabo A, et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003;46:856-868.
8. Wolf G, Ziyadeh FN. Molecular mechanisms of diabetic renal hypertrophy. Kindey Int 1999;56:393-405.
9. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495-2508.
10. Liu BC, Chen Q, Luo DD, et al. Mechanisms of irbesartan in prevention of renal lesion in streptozotocin-induced diabetic rats. Acta Pharmacol Sin 2003;24:67-73.
11. Wolf G. Molecular mechanisms of renal hypertrophy: role of p27Kip1. Kidney Int 1999;56:1262-1265.
12. 4Cl in culture renal proximal tubule cells. J Am Soc Nephrol 1996;7:73-80.
13. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Eng J Med 1996;334:939-945.
14. Jafar TH, Schmid CH, Levey AS. Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med 2002;137:298-299.
15. Zhang SL, Filep JG, Hohman TC, et al. Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells. Kidney Int 1999;55: 454-464.
16. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan in the development of diabetic nephropathy in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:870-878.